{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:26:54Z","timestamp":1783618014326,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>An 8-year-old boy developed anorexia, fatigue, and fever. Laboratory examination revealed a high white blood cell (WBC) count of 145\u00d710<jats:sup>3<\/jats:sup>\/\u03bcL with 97.5% abnormal promyelocytic cells that contained Auer bodies. Faggot cells were seen. He was diagnosed with acute promyelocytic leukemia. Later, a chromosome analysis showed 46,XY,t(15;17)(q22;q12). Promyelocytic Leukemia-retinoic acid receptor \u03b1-fused gene and chimeric mRNA were confirmed by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction, respectively. He was complicated with disseminated intravascular coagulation (DIC) and his fibrin and fibrinogen degradation product at the onset was 37.6 \u03bcg\/mL. Human recombinant thrombomodulin (rTM) was started for DIC. After dexamethasone was administered at a dose of 8 mg\/m<jats:sup>2<\/jats:sup> to prevent all-trans retinoic acid syndrome on day 1, all-trans retinoic acid was started at a dose of 45 mg\/m<jats:sup>2<\/jats:sup> on day 4. Cytarabine (100 mg\/m<jats:sup>2<\/jats:sup>\/d) and daunorubicin (45 mg\/m<jats:sup>2<\/jats:sup>\/d) were started on day 9. The WBC count gradually increased to 270\u00d710<jats:sup>3<\/jats:sup>\/\u03bcL on day 8, and then decreased beginning on day 9. DIC improved after the initiation of chemotherapy and only minor petechia was noted. DIC did not become worse even after rTM was stopped on day 8. The risk of DIC and bleeding is high in the early stage of treatment for acute promyelocytic leukemia, especially in patients with a high WBC count. In our patient, rTM may have prevented fatal DIC and made it possible to safely administer induction chemotherapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000000585","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T12:45:01Z","timestamp":1461847501000},"page":"e189-e190","source":"Crossref","is-referenced-by-count":4,"title":["DIC Complicating APL Successfully Treated With Recombinant Thrombomodulin Alfa"],"prefix":"10.1097","volume":"38","author":[{"given":"Aki","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manaka","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","article-title":"Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort","volume":"133","author":"Matsushita","year":"2014","journal-title":"Thromb Res"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation\u22656: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-013-1463-0","article-title":"Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin","volume":"100","author":"Ikezoe","year":"2014","journal-title":"Int J Hematol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2013.05.007","article-title":"Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death","volume":"37","author":"Altman","year":"2013","journal-title":"Leuk Res"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thromres.2013.03.012","article-title":"The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation","volume":"131","author":"Iba","year":"2013","journal-title":"Thromb Res"},{"key":"R8-20230918","first-page":"CD008562","article-title":"Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia","volume":"6","author":"Mart\u00ed-Carvajal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jth.12155","article-title":"Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines","volume":"11","author":"Wada","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1542\/peds.2012-1466","article-title":"A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin \u03b1","volume":"131","author":"Honda","year":"2013","journal-title":"Pediatrics"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2141.2010.08135.x","article-title":"Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin","volume":"149","author":"Ogawa","year":"2010","journal-title":"Br J Haematol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2015.03.029","article-title":"Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy","volume":"136","author":"Takezako","year":"2015","journal-title":"Thromb Res"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","article-title":"Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation","volume":"36","author":"Ikezoe","year":"2012","journal-title":"Leuk Res"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2169\/internalmedicine.52.7978","article-title":"Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201608000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:01:13Z","timestamp":1695009673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201608000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000585","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}